Aktiesnakken — December 2010
-
men nogle analyser er mere lødige end andre.... fallit suisse's analyse på genmab med kursmål 40 eller var det 60 med 25% discount rate
-
på dcf'en...oveni en sandsynlighedsvægt på arzerra var "under lavmålet" i mine øjne og udtryk for at analytikere også er lemminge og ikke
-
jeg foretrækker det noget mere korrekte Kreditfissen
-
tør stå alene.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
